MSC-Cyt for GvHD
Graft vs. Host Disease
Pre-clinicalActive
Key Facts
About Kyttaro
Kyttaro Therapeutics is a private, preclinical-stage biotech leveraging a proprietary platform of genetically modified mesenchymal stem cells (MSCs). With a foundation in 15 years of R&D and a portfolio of 58 patents, the company is advancing programs in Graft vs. Host Disease (GvHD), Type 1 Diabetes, kidney disease, and combination therapies with CAR-T. Headquartered in Munich, Kyttaro is preparing to initiate clinical trials for its lead GvHD program in Europe and the US while seeking partnerships to expand its pipeline.
View full company profile